Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16706061 | 0.89 | APP (0.45) | NQO1SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL27961979 | 0.88 | NQO1 (0.61) | NQO1SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL13464244 | 0.86 | NQO1 (0.58) | NQO1SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL146457 | 0.83 | NOTUM (0.55) | SMN1; SMN2RAB9ATP53KDM4EHSD17B10 | |
| SCHEMBL6659106 | 0.80 | PPARD (0.41) | SMN1; SMN2NPC1RAB9ATP53KDM4E | |
| SCHEMBL6659098 | 0.80 | PPARD (0.41) | SMN1; SMN2NPC1RAB9ATP53KDM4E | |
| SCHEMBL22510526 | 0.80 | NQO1 (0.50) | NQO1SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL9927249 | 0.79 | APP (0.48) | SMN1; SMN2NPC1RAB9ATP53KDM4E | |
| SCHEMBL19626493 | 0.79 | AOC3 (0.57) | NQO1SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL1105472 | 0.79 | APP (0.76) | SMN1; SMN2NPC1RAB9ATP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651658-B2 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-08-12 | — | — | EP | disclosed |
| EP-3251679-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-12-06 | — | — | EP | disclosed |
| EP-2896397-B1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| EP-2896397-A1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-07-22 | — | — | EP | disclosed |
| EP-2514756-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8785403-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8222219-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8202984-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-8202984-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7943788-B2 | Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943788-B2 | Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-1398027-B1 | Use of matrix metalloproteinase inhibitors for treating or preventing glomerulopathy | SHIONOGI & CO (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | NQO1 83/4885SMN1; SMN2 3474/4885NPC1 443/4885 |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | NQO1 83/4885SMN1; SMN2 3474/4885NPC1 443/4885 |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | NQO1 83/4885SMN1; SMN2 3474/4885NPC1 443/4885 |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | NQO1 83/4885SMN1; SMN2 3474/4885NPC1 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.